Gambaran Umum
Pharvaris N.V., based in the Netherlands, is a biopharmaceutical company primarily engaged in the discovery and development of novel oral therapies for the treatment of hereditary angioedema (HAE) and other related conditions. The company focuses on creating small-molecule alternatives to injected therapies for HAE, a rare genetic disorder characterized by recurring swelling attacks. A key project includes the development of PHA121, an oral bradykinin B2 receptor antagonist, designed to provide a rapid, reliable, and durable response in the acute treatment of HAE symptoms. By innovating oral treatment options, Pharvaris aims to improve accessibility and quality of life for patients suffering from this debilitating condition.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai operating income untuk Pharvaris N.V. per 2025 Jun 30 adalah -165.55 MM.
- Nilai net income untuk Pharvaris N.V. per 2025 Jun 30 adalah -168.29 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | -165.55 | -168.29 | |
2025-03-31 | -159.56 | -152.54 | |
2024-12-31 | -145.69 | -134.22 | |
2024-09-30 | -127.78 | -132.21 | |
2024-06-30 | -116.08 | -114.10 | |
2024-03-31 | -104.15 | -106.26 | |
2023-12-31 | -96.91 | -100.88 | |
2023-09-30 | -93.30 | -107.32 | |
2023-06-30 | -89.48 | -92.21 | |
2023-03-31 | -88.41 | -82.94 | |
2022-12-31 | -86.71 | -76.33 | |
2022-09-30 | -79.39 | -49.48 | |
2022-06-30 | -70.33 | -50.13 | |
2022-03-31 | -61.67 | -52.71 | |
2021-12-31 | -54.14 | -42.73 | |
2021-09-30 | -47.66 | -40.95 | |
2021-06-30 | -40.60 | -38.21 | |
2021-03-31 | -33.60 | -28.75 | |
2020-12-31 | -25.01 | -25.99 | |
2020-09-30 | -18.69 | -18.88 |
Laporan Laba Rugi: EPS
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | ||
2025-03-31 | ||
2024-12-31 | ||
2024-09-30 | -2.57 | -2.57 |
2024-06-30 | -2.37 | -2.37 |
2024-03-31 | -2.45 | -2.45 |
2023-12-31 | -2.63 | |
2023-09-30 | -3.00 | -3.00 |
2023-06-30 | -2.71 | -2.71 |
2023-03-31 | -2.46 | -2.46 |
2022-12-31 | -2.27 | |
2022-09-30 | -1.48 | -1.48 |
2022-06-30 | -1.51 | -1.51 |
2022-03-31 | -1.45 | -1.45 |
2021-12-31 | -1.41 | |
2021-09-30 | -1.76 | -1.76 |
2021-06-30 | -2.35 | -2.35 |
2021-03-31 | -4.86 | -4.86 |
2020-12-31 | -5.36 | |
2020-09-30 | -3.89 | -3.89 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk Pharvaris N.V. per 2025 Jun 30 adalah -136.67 MM.
- Nilai cash from investing activities untuk Pharvaris N.V. per 2025 Jun 30 adalah -0.61 MM.
- Nilai kas dari aktivitas pendanaan untuk Pharvaris N.V. per 2025 Jun 30 adalah 1.46 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | -136.67 | -0.61 | 1.46 |
2025-03-31 | -134.37 | -0.67 | 1.81 |
2024-12-31 | -120.13 | -0.54 | 2.68 |
2024-09-30 | -108.99 | -0.41 | 263.84 |
2024-06-30 | -99.28 | -0.11 | 262.73 |
2024-03-31 | -92.08 | -0.10 | 326.24 |
2023-12-31 | -93.05 | -0.09 | 325.39 |
2023-09-30 | -89.65 | -0.09 | 63.50 |
2023-06-30 | -81.28 | -0.13 | 63.61 |
2023-03-31 | -74.49 | -0.12 | 8.70 |
2022-12-31 | -67.16 | -0.12 | 8.65 |
2022-09-30 | -59.25 | -0.17 | 8.19 |
2022-06-30 | -54.11 | -0.15 | 8.19 |
2022-03-31 | -52.28 | -0.15 | -0.44 |
2021-12-31 | -44.60 | -0.13 | 143.67 |
2021-09-30 | -41.01 | -0.07 | 211.25 |
2021-06-30 | -37.59 | -0.06 | 245.51 |
2021-03-31 | -29.37 | -0.04 | 245.20 |
2020-12-31 | -21.50 | -0.04 | 101.20 |
2020-09-30 | -15.74 | -0.04 | 33.58 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | |||
2025-03-31 | |||
2024-12-31 | |||
2024-09-30 | |||
2024-06-30 | |||
2024-03-31 | |||
2023-12-31 | |||
2023-09-30 | |||
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | |||
2021-12-31 | |||
2021-09-30 | |||
2021-06-30 | |||
2021-03-31 | |||
2020-12-31 | |||
2020-09-30 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | ||
2025-03-31 | ||
2024-12-31 | ||
2024-09-30 | ||
2024-06-30 | ||
2024-03-31 | ||
2023-12-31 | ||
2023-09-30 | ||
2023-06-30 | ||
2023-03-31 | ||
2022-12-31 | ||
2022-09-30 | ||
2022-06-30 | ||
2022-03-31 | ||
2021-12-31 | ||
2021-09-30 | ||
2021-06-30 | ||
2021-03-31 | ||
2020-12-31 | ||
2020-09-30 |
Efektivitas Manajemen
- roa untuk Pharvaris N.V. pada 2025 Jun 30 adalah -0.43.
- roe untuk Pharvaris N.V. pada 2025 Jun 30 adalah -0.46.
- roic untuk Pharvaris N.V. pada 2025 Jun 30 adalah -0.67.
- croic untuk Pharvaris N.V. pada 2025 Jun 30 adalah -0.58.
- ocroic untuk Pharvaris N.V. pada 2025 Jun 30 adalah -0.59.
Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
2025-06-30 | -0.43 | -0.46 | -0.67 | -0.58 | -0.59 |
2025-03-31 | -0.35 | -0.37 | -0.45 | 0.49 | -0.37 |
2024-12-31 | -0.33 | -0.34 | -0.45 | 0.49 | -0.37 |
2024-09-30 | -0.67 | -0.75 | -0.34 | 0.49 | -0.30 |
2024-06-30 | -0.72 | -0.82 | -0.30 | 0.65 | -0.26 |
2024-03-31 | -0.64 | -0.72 | -0.70 | -0.26 | -0.58 |
2023-12-31 | -0.53 | -0.58 | -0.70 | -0.26 | -0.58 |
2023-09-30 | -0.45 | -0.48 | -0.53 | -0.13 | -0.47 |
2023-06-30 | -0.40 | -0.44 | -0.53 | -0.13 | -0.47 |
2023-03-31 | -0.25 | -0.26 | -0.64 | -0.46 | -0.58 |
2022-12-31 | -0.22 | -0.27 | -0.11 | -0.32 | |
2022-09-30 | -0.22 | -0.23 | -0.27 | -0.11 | -0.32 |
2022-06-30 | -0.23 | -0.24 | -0.26 | -0.12 | -0.28 |
2022-03-31 | -0.18 | -0.18 | -0.28 | -0.23 | -0.27 |
2021-12-31 | -0.38 | -0.40 | -0.21 | 0.54 | -0.17 |
2021-09-30 | -0.95 | -0.99 | -0.20 | 0.86 | -0.17 |
2021-06-30 | -1.86 | -2.05 | -0.17 | 0.94 | -0.17 |
2021-03-31 | -1.40 | -1.54 | -0.12 | 0.94 | -0.12 |
2020-12-31 | -1.26 | -1.39 | -0.27 | 0.82 | -0.22 |
2020-09-30 | -0.49 | 0.46 | -0.41 |
Gross Margins
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
2025-06-30 | |||
2025-03-31 | |||
2024-12-31 | |||
2024-09-30 | |||
2024-06-30 | |||
2024-03-31 | |||
2023-12-31 | |||
2023-09-30 | |||
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | |||
2021-12-31 | |||
2021-09-30 | |||
2021-06-30 | |||
2021-03-31 | |||
2020-12-31 | |||
2020-09-30 |
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK) | 1830487 |
Grupong Pang-industriya
SIC 2834 - Pharmaceutical Preparations |